Yunnan Lincang Xinyuan Germanium Industry (002428.SZ) plans to establish controlling interests in Yunge Germanium Biotechnology to carry out organic germanium-related businesses.
Yunnan Germanium Industry (002428.SZ) announced that the board of directors has approved the proposal to establish a wholly-owned subsidiary through external investment. The company has agreed to jointly invest 10 million yuan with Kunming Haliwa Enterprise Management Partnership Enterprise (Limited Partnership) (referred to as "Kunming Haliwa") to establish Yunnan Germanium Biological Technology Co., Ltd. (tentative name, referred to as "Yunzhe Biology"). Yunzhe Biology is mainly engaged in the development of daily chemical products and other organic germanium related application products with organic germanium as the core.
Yunnan Lincang Xinyuan Germanium Industry (002428.SZ) announced that the board of directors has approved the proposal to establish a holding subsidiary through external investment. The company agrees to jointly invest 10 million yuan with Kunming Haheva Enterprise Management Partnership Enterprise (Limited Partnership) (referred to as "Kunming Haheva") to establish the holding subsidiary Yunnan Lincang Xinyuan Germanium Industry Biotechnology Co., Ltd. (tentative name, referred to as "Yunzhi Biotech"). Yunzhi Biotech is mainly engaged in the development of daily chemical products and other organic germanium-related application products with organic germanium as the core.
Related Articles
On December 12, JXR (01951) spent 19.3521 million Hong Kong dollars to buy back 7.722 million shares.
Jiangsu Hengrui Pharmaceuticals (01276): HRS-1780 tablets receive approval notice for drug clinical trials.
Shennan Circuits (002916.SZ) plans to grant 15.16 million restricted shares.
On December 12, JXR (01951) spent 19.3521 million Hong Kong dollars to buy back 7.722 million shares.
Jiangsu Hengrui Pharmaceuticals (01276): HRS-1780 tablets receive approval notice for drug clinical trials.
Shennan Circuits (002916.SZ) plans to grant 15.16 million restricted shares.
